RELVAR ELLIPTA Inhaler / Dry Powder
Futicasone (as furoate), Vilanterol (as trifenatate)
"200mcg, 25mcg/12.5mg (184mcg, 22mcg/Dose)"
GLAXO OPERATIONS UK LIMITED
| Pack size | 30 Doses Inhaler |
|---|---|
| Dispensing mode | POM |
| Source | UK |
| Agent | AL ITTIHAD DRUG STORE |
| Retail Price | 335.50 AED |
Indications
RELVAR ELLIPTA Inhaler / Dry Powder is used for:
FLUTICASONE FUROATE
Fluticasone furoate nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older. Breo ellipta, a mixture of fluticasone furoate and vilanterol is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease. Breo ellipta should not be used for the relief of acute symptoms of asthma or copd
VILANTEROL
Vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename breo ellipta and in combination with umeclidinium bromide as anoro ellipta. Approved by the fda in 2013, use of breo ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease
Fluticasone furoate nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older. Breo ellipta, a mixture of fluticasone furoate and vilanterol is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease. Breo ellipta should not be used for the relief of acute symptoms of asthma or copd
VILANTEROL
Vilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename breo ellipta and in combination with umeclidinium bromide as anoro ellipta. Approved by the fda in 2013, use of breo ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with copd, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Futicasone (as furoate), Vilanterol (as trifenatate) :
Mechanism of Action
FLUTICASONE FUROATE
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. The precise mechanism through which fluticasone furoate affects rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e. G. , mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e. G. , histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Specific effects of fluticasone furoate demonstrated in in vitro and in vivo models included activation of the glucocorticoid response element, inhibition of pro-inflammatory transcription factors such as nfkb, and inhibition of antigen-induced lung eosinophilia in sensitized rats. Fluticasone is also found to increase airway retention of long-acting beta adrenergic agonist, thus potentiating its beneficial effects for the treatment of asthma
VILANTEROL
Vilanterol is a selective long-acting beta2-adrenergic agonist. Its pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (atp) to cyclic-3',5'-adenosine monophosphate (camp). Increases in cyclic amp are associated with relaxation of bronchial smooth muscle and inhibition of release of hypersensitivity mediators from mast cells in the lungs
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. The precise mechanism through which fluticasone furoate affects rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e. G. , mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e. G. , histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Specific effects of fluticasone furoate demonstrated in in vitro and in vivo models included activation of the glucocorticoid response element, inhibition of pro-inflammatory transcription factors such as nfkb, and inhibition of antigen-induced lung eosinophilia in sensitized rats. Fluticasone is also found to increase airway retention of long-acting beta adrenergic agonist, thus potentiating its beneficial effects for the treatment of asthma
VILANTEROL
Vilanterol is a selective long-acting beta2-adrenergic agonist. Its pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (atp) to cyclic-3',5'-adenosine monophosphate (camp). Increases in cyclic amp are associated with relaxation of bronchial smooth muscle and inhibition of release of hypersensitivity mediators from mast cells in the lungs
Note
RELVAR ELLIPTA "200mcg, 25mcg/12.5mg (184mcg, 22mcg/Dose)" Inhaler / Dry Powder manufactured by GLAXO OPERATIONS UK LIMITED. Its generic name is Futicasone (as furoate), Vilanterol (as trifenatate). RELVAR ELLIPTA is availble in United Arab Emirates.
Farmaco UAE drug index information on RELVAR ELLIPTA Inhaler / Dry Powder is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.